CO2018005229A2 - Vacuna de virus sincitial respiratorio - Google Patents
Vacuna de virus sincitial respiratorioInfo
- Publication number
- CO2018005229A2 CO2018005229A2 CONC2018/0005229A CO2018005229A CO2018005229A2 CO 2018005229 A2 CO2018005229 A2 CO 2018005229A2 CO 2018005229 A CO2018005229 A CO 2018005229A CO 2018005229 A2 CO2018005229 A2 CO 2018005229A2
- Authority
- CO
- Colombia
- Prior art keywords
- vaccines
- rsv
- respiratory syncytial
- syncytial virus
- rna
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción se refiere a vacunas de virus sincitial respiratorio (RSV). Las vacunas incluyen al menos un polinucleótido de ácido ribonucleico (ARN) que tiene un marco de lectura abierto que codifica al menos un polipéptido antigénico de RSV o un fragmento inmunógeno de este y un portador farmacéuticamente aceptable. También se describen métodos para aplicar las vacunas y las composiciones que comprenden las vacunas. Las vacunas de ARN de RSV, tal como se proporcionan en la presente, pueden usarse para inducir una respuesta inmunitaria equilibrada contra el RSV, que comprende tanto inmunidad celular como humoral, sin arriesgar la posibilidad de mutagénesis insercional entre otros riesgos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562245208P | 2015-10-22 | 2015-10-22 | |
US201562245031P | 2015-10-22 | 2015-10-22 | |
US201562247563P | 2015-10-28 | 2015-10-28 | |
US201562248250P | 2015-10-29 | 2015-10-29 | |
PCT/US2016/058321 WO2017070622A1 (en) | 2015-10-22 | 2016-10-21 | Respiratory syncytial virus vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018005229A2 true CO2018005229A2 (es) | 2018-11-30 |
Family
ID=58558153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0005229A CO2018005229A2 (es) | 2015-10-22 | 2018-05-18 | Vacuna de virus sincitial respiratorio |
Country Status (20)
Country | Link |
---|---|
US (2) | US20180271970A1 (es) |
EP (1) | EP3365008A4 (es) |
JP (2) | JP2019501208A (es) |
KR (1) | KR20180096592A (es) |
CN (1) | CN108472354A (es) |
AU (1) | AU2016341311B2 (es) |
BR (1) | BR112018008102A2 (es) |
CA (1) | CA3002820A1 (es) |
CL (1) | CL2018001053A1 (es) |
CO (1) | CO2018005229A2 (es) |
EA (1) | EA201891000A1 (es) |
IL (1) | IL258831A (es) |
MA (1) | MA46317A (es) |
MX (1) | MX2018004917A (es) |
PE (1) | PE20181530A1 (es) |
PH (1) | PH12018500856A1 (es) |
SG (2) | SG10201914006UA (es) |
TN (1) | TN2018000154A1 (es) |
TW (1) | TW201729836A (es) |
WO (1) | WO2017070622A1 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
KR20180094859A (ko) | 2015-10-22 | 2018-08-24 | 모더나티엑스, 인크. | 수두 대상포진 바이러스 (vzv)를 위한 핵산 백신 |
EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
MD3718565T2 (ro) | 2015-10-22 | 2022-09-30 | Modernatx Inc | Vaccinuri împotriva virusului respirator |
CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
US20180289792A1 (en) | 2015-10-22 | 2018-10-11 | ModernaTX. Inc. | Sexually transmitted disease vaccines |
EP3964200A1 (en) | 2015-12-10 | 2022-03-09 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
EP3452493A1 (en) * | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
SG11201810256XA (en) | 2016-05-18 | 2018-12-28 | Modernatx Inc | Polynucleotides encoding relaxin |
ES2928475T3 (es) | 2016-09-14 | 2022-11-18 | Modernatx Inc | Composiciones de ARN de alta pureza y métodos para su preparación |
MA46584A (fr) | 2016-10-21 | 2019-08-28 | Modernatx Inc | Vaccin contre le cytomégalovirus humain |
WO2018089851A2 (en) | 2016-11-11 | 2018-05-17 | Modernatx, Inc. | Influenza vaccine |
MA50335A (fr) | 2016-12-08 | 2020-08-19 | Modernatx Inc | Vaccins à acide nucléique contre des virus respiratoires |
WO2018111967A1 (en) | 2016-12-13 | 2018-06-21 | Modernatx, Inc. | Rna affinity purification |
MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
MA47787A (fr) * | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
US20200030432A1 (en) | 2017-03-17 | 2020-01-30 | Modernatx, Inc. | Zoonotic disease rna vaccines |
MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
MA49922A (fr) | 2017-08-18 | 2021-06-02 | Modernatx Inc | Procédés pour analyse par clhp |
EP3668971B8 (en) | 2017-08-18 | 2024-05-29 | ModernaTX, Inc. | Rna polymerase variants |
US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
EP3775174A4 (en) * | 2018-03-30 | 2022-07-06 | Georgia State University Research Foundation, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES |
BR112020020933A2 (pt) | 2018-04-17 | 2021-04-06 | Curevac Ag | Moléculas de rna de rsv inovadoras e composições para vacinação |
MX2021001479A (es) * | 2018-08-07 | 2021-04-28 | Glaxosmithkline Biologicals Sa | Novedosos procesos y vacunas. |
US20210378980A1 (en) * | 2018-09-20 | 2021-12-09 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
KR20200050264A (ko) * | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
EP3937963A2 (en) | 2019-03-12 | 2022-01-19 | CRISPR Therapeutics AG | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
CN115778904A (zh) * | 2019-10-29 | 2023-03-14 | 珠海丽凡达生物技术有限公司 | 一种用于体外转染和体内递送mRNA的制剂 |
EP4096683A4 (en) * | 2020-01-30 | 2024-04-10 | ModernaTX, Inc. | IMMUNIZATION COMPOSITIONS FOR RESPIRATORY VIRUSES |
GB202307565D0 (en) | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
BR112022024248A2 (pt) | 2020-05-29 | 2023-10-10 | CureVac SE | Vacinas de combinação à base de ácido nucleico |
US20220002716A1 (en) | 2020-07-02 | 2022-01-06 | Life Technologies Corporation | Trinucleotide cap analogs, preparation and uses thereof |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN111973563B (zh) * | 2020-09-02 | 2022-06-28 | 崔海港 | 一种鼠李糖脂冻干粉制剂及其制备方法和应用 |
TW202233232A (zh) * | 2020-11-06 | 2022-09-01 | 法商賽諾菲公司 | 遞送mRNA疫苗的脂質奈米顆粒 |
US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
AU2022290382A1 (en) | 2021-06-11 | 2023-11-23 | Bayer Aktiengesellschaft | Type v rna programmable endonuclease systems |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
IL309505A (en) | 2021-09-03 | 2024-02-01 | CureVac SE | Lipid nanoparticles for nucleic acid delivery |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
WO2024129743A2 (en) | 2022-12-13 | 2024-06-20 | Bluerock Therapeutics Lp | Engineered type v rna programmable endonucleases and their uses |
CN117487823A (zh) * | 2023-09-28 | 2024-02-02 | 怡道生物科技(苏州)有限公司 | 呼吸道合胞体病毒mRNA疫苗及其制备方法和应用 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6998115B2 (en) | 2000-10-10 | 2006-02-14 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
US7708915B2 (en) | 2004-05-06 | 2010-05-04 | Castor Trevor P | Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein |
DE50214200D1 (de) | 2001-06-05 | 2010-03-25 | Curevac Gmbh | Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt |
AU2002319668A1 (en) | 2001-07-27 | 2003-02-17 | President And Fellows Of Harvard College | Laminar mixing apparatus and methods |
EP1443905A4 (en) | 2001-10-03 | 2010-06-23 | Univ Johns Hopkins | COMPOSITIONS FOR ORAL GENE THERAPY AND METHOD OF USE THEREOF |
WO2003092665A2 (en) | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
NZ570709A (en) * | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
EP1713514B1 (en) | 2004-01-28 | 2021-11-24 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
AU2005329255B2 (en) | 2004-04-15 | 2010-09-30 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
US8354476B2 (en) | 2004-12-10 | 2013-01-15 | Kala Pharmaceuticals, Inc. | Functionalized poly(ether-anhydride) block copolymers |
EP1907444B1 (en) | 2005-04-01 | 2009-08-19 | Intezyne Technologies Incorporated | Polymeric micelles for drug delivery |
WO2006110776A2 (en) | 2005-04-12 | 2006-10-19 | Nektar Therapeutics Al, Corporation | Polyethylene glycol cojugates of antimicrobial agents |
EP2279758B1 (en) | 2005-06-16 | 2015-02-25 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
CN103030801B (zh) | 2006-02-21 | 2015-07-22 | 尼克塔治疗公司 | 嵌段可降解聚合物及由其制备的轭合物 |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
CA2663003C (en) | 2006-09-08 | 2018-02-13 | Justin Hanes | Compositions and methods for enhancing transport through mucus |
CA2671925A1 (en) | 2006-12-21 | 2008-07-10 | Stryker Corporation | Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents |
EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
WO2010005721A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
US20100104645A1 (en) | 2008-06-16 | 2010-04-29 | Bind Biosciences, Inc. | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
KR102344392B1 (ko) * | 2008-11-10 | 2021-12-28 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
ES2776126T3 (es) | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
AU2010208035B2 (en) * | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
JP5622254B2 (ja) | 2009-03-31 | 2014-11-12 | 国立大学法人東京大学 | 二本鎖リボ核酸ポリイオンコンプレックス |
US8287910B2 (en) | 2009-04-30 | 2012-10-16 | Intezyne Technologies, Inc. | Polymeric micelles for polynucleotide encapsulation |
CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
WO2011084521A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
EA201290497A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
ES2536429T3 (es) | 2010-01-24 | 2015-05-25 | Novartis Ag | Micropartículas de polímero biodegradables irradiadas |
WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
US20130196948A1 (en) | 2010-06-25 | 2013-08-01 | Massachusetts Insitute Of Technology | Polymers for biomaterials and therapeutics |
RS63817B1 (sr) * | 2010-07-06 | 2023-01-31 | Glaxosmithkline Biologicals Sa | Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk |
EP2590626B1 (en) * | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
WO2012006369A2 (en) * | 2010-07-06 | 2012-01-12 | Novartis Ag | Immunisation of large mammals with low doses of rna |
WO2012039979A2 (en) | 2010-09-10 | 2012-03-29 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
EP2629760A4 (en) | 2010-10-22 | 2014-04-02 | Bind Therapeutics Inc | THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT |
WO2012061703A1 (en) | 2010-11-05 | 2012-05-10 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
US20120189700A1 (en) | 2011-01-19 | 2012-07-26 | Zoraida Aguilar | Nanoparticle Based Immunological Stimulation |
US20140066363A1 (en) | 2011-02-07 | 2014-03-06 | Arun K. Bhunia | Carbohydrate nanoparticles for prolonged efficacy of antimicrobial peptide |
ES2820369T3 (es) | 2011-03-31 | 2021-04-20 | Ingell Tech Holding B V | Composiciones biodegradables adecuadas para liberación controlada |
EP2691078A1 (en) | 2011-03-31 | 2014-02-05 | Ingell Technologies Holding B.V. | Biodegradable compositions suitable for controlled release |
US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
WO2012166923A2 (en) | 2011-05-31 | 2012-12-06 | Bind Biosciences | Drug loaded polymeric nanoparticles and methods of making and using same |
JP2014520806A (ja) * | 2011-07-06 | 2014-08-25 | ノバルティス アーゲー | Rna分子の送達のための有用なn:p比を有するリポソーム |
ES2702318T3 (es) * | 2011-07-06 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
CN103732211B (zh) | 2011-07-21 | 2017-03-01 | 禾大国际股份公开有限公司 | 支化的聚醚‑聚酰胺嵌段共聚物及其制造与使用方法 |
US8932572B2 (en) | 2011-08-26 | 2015-01-13 | Arrowhead Madison Inc. | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
CN103930135A (zh) | 2011-08-31 | 2014-07-16 | 马林克罗特有限公司 | 使用h-膦酸酯的纳米颗粒peg修饰 |
US20150017245A1 (en) | 2011-09-22 | 2015-01-15 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
CA2852917C (en) | 2011-10-18 | 2020-07-07 | Dicerna Pharmaceuticals, Inc. | Amine cationic lipids and uses thereof |
AU2012328570B2 (en) | 2011-10-27 | 2017-08-31 | Massachusetts Institute Of Technology | Amino acid derivatives functionalized on the n-terminus capable of forming drug encapsulating microspheres and uses thereof |
WO2013078199A2 (en) | 2011-11-23 | 2013-05-30 | Children's Medical Center Corporation | Methods for enhanced in vivo delivery of synthetic, modified rnas |
CN104114572A (zh) | 2011-12-16 | 2014-10-22 | 现代治疗公司 | 经修饰的核苷、核苷酸和核酸组合物 |
KR101811917B1 (ko) | 2012-01-19 | 2017-12-22 | 더 존스 홉킨스 유니버시티 | 점액 침투 강화를 나타내는 나노 입자 제형 |
CA3069030C (en) | 2012-02-03 | 2021-11-16 | Rutgers, The State University Of New Jersey | Polymeric biomaterials derived from phenolic monomers and their medical uses |
US20150337068A1 (en) | 2012-02-10 | 2015-11-26 | Karl K Berggren | Preparation, purification and use of high-x diblock copolymers |
DE18200782T1 (de) * | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
EA201492055A1 (ru) * | 2012-06-08 | 2015-11-30 | Шир Хьюман Дженетик Терапис, Инк. | ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ |
EP2929035A1 (en) * | 2012-12-07 | 2015-10-14 | Shire Human Genetic Therapies, Inc. | Lipidic nanoparticles for mrna delivering |
CN112851766A (zh) * | 2013-03-13 | 2021-05-28 | 美国政府(由卫生和人类服务部的部长所代表) | 融合前rsv f蛋白和其用途 |
US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
HUE055044T2 (hu) * | 2013-03-14 | 2021-10-28 | Translate Bio Inc | MRNS-kódolt ellenanyagok bejuttatására szolgáló eljárások és készítmények |
WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
ES2795249T3 (es) * | 2013-03-15 | 2020-11-23 | Translate Bio Inc | Mejora sinérgica de la administración de ácidos nucleicos a través de formulaciones mezcladas |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
TW201534578A (zh) * | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
WO2015013551A1 (en) * | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
MX369469B (es) * | 2013-08-21 | 2019-11-08 | Curevac Ag | Vacuna contra el virus respiratorio sincitial. |
-
2016
- 2016-10-21 BR BR112018008102A patent/BR112018008102A2/pt not_active Application Discontinuation
- 2016-10-21 PE PE2018000599A patent/PE20181530A1/es unknown
- 2016-10-21 CN CN201680075062.6A patent/CN108472354A/zh active Pending
- 2016-10-21 WO PCT/US2016/058321 patent/WO2017070622A1/en active Application Filing
- 2016-10-21 TN TNP/2018/000154A patent/TN2018000154A1/en unknown
- 2016-10-21 EP EP16858402.7A patent/EP3365008A4/en active Pending
- 2016-10-21 SG SG10201914006UA patent/SG10201914006UA/en unknown
- 2016-10-21 AU AU2016341311A patent/AU2016341311B2/en not_active Expired - Fee Related
- 2016-10-21 MA MA046317A patent/MA46317A/fr unknown
- 2016-10-21 JP JP2018541089A patent/JP2019501208A/ja active Pending
- 2016-10-21 CA CA3002820A patent/CA3002820A1/en active Pending
- 2016-10-21 KR KR1020187014339A patent/KR20180096592A/ko unknown
- 2016-10-21 SG SG11201803363YA patent/SG11201803363YA/en unknown
- 2016-10-21 US US15/767,613 patent/US20180271970A1/en not_active Abandoned
- 2016-10-21 MX MX2018004917A patent/MX2018004917A/es unknown
- 2016-10-21 TW TW105134193A patent/TW201729836A/zh unknown
- 2016-10-21 EA EA201891000A patent/EA201891000A1/ru unknown
-
2018
- 2018-04-20 PH PH12018500856A patent/PH12018500856A1/en unknown
- 2018-04-20 CL CL2018001053A patent/CL2018001053A1/es unknown
- 2018-04-22 IL IL258831A patent/IL258831A/en unknown
- 2018-05-18 CO CONC2018/0005229A patent/CO2018005229A2/es unknown
-
2022
- 2022-10-27 JP JP2022172576A patent/JP2023015151A/ja active Pending
-
2023
- 2023-05-10 US US18/314,980 patent/US20230390379A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3365008A1 (en) | 2018-08-29 |
MA46317A (fr) | 2019-08-07 |
TN2018000154A1 (en) | 2019-10-04 |
EA201891000A1 (ru) | 2018-12-28 |
PE20181530A1 (es) | 2018-09-26 |
PH12018500856A1 (en) | 2018-10-29 |
JP2023015151A (ja) | 2023-01-31 |
SG10201914006UA (en) | 2020-03-30 |
CA3002820A1 (en) | 2017-04-27 |
US20230390379A1 (en) | 2023-12-07 |
CL2018001053A1 (es) | 2018-10-19 |
SG11201803363YA (en) | 2018-05-30 |
WO2017070622A1 (en) | 2017-04-27 |
IL258831A (en) | 2018-06-28 |
KR20180096592A (ko) | 2018-08-29 |
CN108472354A (zh) | 2018-08-31 |
US20180271970A1 (en) | 2018-09-27 |
TW201729836A (zh) | 2017-09-01 |
JP2019501208A (ja) | 2019-01-17 |
BR112018008102A2 (pt) | 2018-11-06 |
AU2016341311A1 (en) | 2018-06-07 |
AU2016341311B2 (en) | 2023-11-16 |
MX2018004917A (es) | 2019-04-01 |
EP3365008A4 (en) | 2019-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
CO2018005258A2 (es) | Vacuna del virus herpes simple | |
CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
WO2017070626A3 (en) | Respiratory virus vaccines | |
WO2018089851A3 (en) | Influenza vaccine | |
MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
WO2016109792A3 (en) | Novel multivalent nanoparticle-based vaccines | |
WO2015142671A3 (en) | Influenza virus vectors and uses therefor | |
WO2015052543A3 (en) | Malaria vaccination | |
MX2019003682A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
EP2873423A3 (en) | Soluble hiv-1 envelope glycoprotein trimers | |
PH12015501716A1 (en) | Anti-mycoplasma spp. subunit vaccine | |
AU2014232363A8 (en) | Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom | |
NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
MX2016001695A (es) | Composiciones inmunogenas de combinacion. | |
MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
WO2016157208A9 (en) | Recombinant mumps virus jeryl lynn 2 based vaccine | |
EA033027B1 (ru) | Ослабленные вакцины от свиного гриппа и способы их получения и применения | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2023011129A (es) | Mutantes del virus de la influenza b y usos de los mismos. | |
AR106464A1 (es) | Vacuna de virus sincitial respiratorio |